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BI 811283, an adenosine triphosphate-competitive, reversible and potent inhibitor of Aurora B 57 
kinase, has demonstrated antitumor activity in acute myeloid leukaemia (AML) cell lines (Gürtler 58 
et al, 2010a; Gürtler et al, 2010b; Mross et al, 2016; Tontsch-Grunt et al, 2010). Here we report 59 
a phase I trial that evaluated the maximum tolerated dose (MTD), safety, efficacy and 60 
pharmacokinetics (PK) of BI 811283 with low-dose cytarabine (LDAC) in patients with AML 61 
considered ineligible for intensive treatment (NCT00632749). 62 
Patients with previously untreated (except hydroxyurea) or relapsed/refractory AML 63 
(excluding acute promyelocytic leukaemia) considered unsuitable for intensive induction or 64 
salvage therapy were randomized to one of two schedules, combining BI 811283 (24-hour 65 
intravenous infusion; 4-week cycle) with LDAC (20 mg twice daily subcutaneously; days 1–10 of 66 
a 4-week cycle). In Schedule A, patients received BI 811283 on days 1 and 15. In Schedule B, 67 
patients received BI 811283 on day 1. BI 811283 dose escalation followed a 3+3 design 68 
(BI 811283 starting dose: 5 mg).  69 
The primary endpoint was to determine the MTD of the two BI 811283 schedules in 70 
combination with LDAC based on the incidence of DLTs. Further endpoints included: incidence 71 
and intensity of AEs, response, PK of cytarabine with BI 811283. Full methodological details are 72 
in the Supporting Information. All patients provided written informed consent. The trial was 73 
registered at ClinicalTrials.gov (NCT00632749). 74 
 Of 68 randomised patients, 64 were treated; (Schedule A, n=28; Schedule B, n=36). At 75 
baseline (Table SI), 11 (17·2%), 37 (57·8%) and 16 (25·0%) patients had an Eastern 76 
Cooperative Oncology Group (ECOG) score of 0, 1 and 2, respectively. Median age was 73 77 
(range, 49–89) years. Forty-four patients (68·8%) were previously untreated for AML and 20 78 
(31·3%) patients had relapsed/refractory disease. Twenty-two patients (34·4%) had adverse-79 
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risk genetics, two patients (3·1%) had favourable-risk genetics, and 20 (31·3%) and six patients 80 
(9·4%) had intermediate-risk I and II genetics, respectively.  81 
 Dose escalations and DLTs are shown in Table I. In Schedule A, DLTs were seen in the 82 
120 mg dose group; the BI 811283 dose was therefore de-escalated to 100 mg and a further 83 
three patients were enrolled. As no DLTs were seen at the 100 mg dose level, the MTD in 84 
Schedule A was determined to be 100 mg. In Schedule B, the BI 811283 dose was escalated to 85 
420 mg without the MTD being reached. Due to a strategic decision by the sponsor to halt 86 
development of BI 811283, recruitment was stopped at the 420 mg dose. 87 
 All treated patients had at least one AE during study participation. The most common 88 
AEs reported in Schedule A were anaemia (53·6%), nausea (50·0%) and pyrexia, febrile 89 
neutropenia and leukopenia (each 39·3%), and in Schedule B were pyrexia (52·8%), 90 
thrombocytopenia (50·0%) and anaemia and nausea (each 47·2%). Grade ≥3 AEs occurring in 91 
>10% of patients in a treatment group are shown by system organ class in Table II and 92 
incidence of AEs by dose in Table SII.  93 
Overall, 82·8% of patients had AEs that were considered drug related by the 94 
investigators. AEs that led to discontinuation were reported in 39·3% of patients in Schedule A 95 
and 25·0% of patients in Schedule B. A total of 26 patients (40·6%) had fatal AEs (10 patients 96 
[35·7%] in Schedule A and 16 [44·4%] in Schedule B), mainly due to infections and AML 97 
progression; only one death (neutropenic sepsis in an 82-year-old female) was considered 98 
related to trial medication.  99 
 The median number of courses completed was 1 (range, 0–3) with Schedule A and 1 100 
(range, 0–15) with Schedule B. The median number of courses was 2 (range, 1–15) for patients 101 
with previously untreated AML and 1 (range, 1–6) for patients with relapsed/refractory AML.  102 
6 
 
Best overall response is presented in Table SIII. In Schedule A, two patients (7·1%) 103 
achieved a complete remission (CR); 10 patients (35·7%) had no change as their best 104 
response, 11 (39·3%) had progressive disease and for five patients (17·9%) no response 105 
assessment was available. In Schedule B, five patients (13.9%) achieved a CR. Additionally, 106 
one patient (2·8%) had a CR with incomplete haematologic recovery (CRi) and one further 107 
patient (2·8%) had a partial remission (PR). Seventeen remaining patients (47·2%) had no 108 
change, eight patients (22·2%) had progressive disease and for four patients (11·1%) no 109 
response assessment was available. In Schedule A, both patients who achieved CR had 110 
previously untreated AML, and in Schedule B, all but one patient who achieved CR, CRi or PR 111 
had previously untreated AML. No dose-related trend in response rate was observed and 112 
responses occurred after a median of 1 cycle of therapy (range, 1–7). For the eight patients 113 
overall who had a best response of CR or CRi, the median remission duration was 263 days 114 
(range, 15–1492).  115 
BI 811283 plasma PK profiles suggested no effect of the dosing schedule on the PK of 116 
BI 811283, and in both treatment schedules, suggested close to dose-proportional PK (Fig S1). 117 
Cytarabine plasma concentration profiles were similar in each BI 811283 dose group (Fig S2) 118 
and the PK parameters of cytarabine did not vary with BI 811283 dose (data not shown), 119 
indicating that cytarabine PK was not influenced by BI 811283. 120 
In summary, this phase I trial demonstrated an acceptable safety profile with BI 811283 121 
administered at two different treatment schedules in combination with LDAC. Other Aurora 122 
kinase inhibitors, including the Aurora B kinase inhibitor barasertib, have demonstrated 123 
encouraging activity as both monotherapy and in combination, in phase I/II trials in patients with 124 
AML (Bavetsias and Linardopoulos 2015). However, the results of this study do not indicate 125 
improved anti-leukaemic activity of BI 811283 in combination with LDAC compared with 126 
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historical results for LDAC alone. The clinical development of BI 811283 was stopped for 127 
strategic reasons, but it has been hypothesized that Aurora kinase inhibition in combination with 128 
inhibition of other key oncogenic drivers in AML (e.g., FMS-like tyrosine kinase receptor-3) may 129 
provide improved outcomes and impede tumour resistance. Therefore, further clinical 130 
exploration of Aurora B kinase as a therapeutic target in AML might be warranted.  131 
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Tables 190 
Table I. DLTs in cycle 1 and for determination of MTD. 191 
BI 811283 dose level Patients 
entered*, n 
Patients with 
DLT, n 
DLTs 
Schedule A    
5 mg  4 0 − 
15 mg  3 0 − 
30 mg  3 0 − 
60 mg  4 0 − 
100 mg  7 0 − 
120 mg  7 2 Grade 3 tumour lysis syndrome (n = 1),  
grade 3 acute renal failure (n = 1) 
Schedule B    
5 mg  4 1 Grade 3 folliculitis (in the context of 
treatment-emergent neutropenia) 
40 mg  4 0 − 
80 mg  5 0 − 
160 mg  3 0 − 
240 mg  7 1 Grade 3 increased transaminases  
300 mg  4 0 − 
360 mg  3 1 Grade 4 hyperuricaemia 
420 mg  6 0 − 
DLT, dose-limiting toxicity; MTD, maximum tolerated dose. 192 
*According to protocol, patients who were not evaluable for DLT (did not complete at least 1 193 
cycle for reasons other than DLT) were replaced for determination of the MTD. Therefore, the 194 
patient number in some dose groups is different from three or six. Fourteen treated patients did 195 
not complete the first treatment cycle for reasons other than DLT (most commonly due to early 196 
progression or non-DLT AEs) and were therefore replaced for determination of the MTD. 197 
198 
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Table II. AEs grade ≥3 occurring by system organ class in >10% of patients (both schedules, all doses, irrespective of relationship to 
trial drug) with preferred term displayed if reported in ≥2 patients in a treatment group. 
System organ class* 
Preferred term 
Schedule A 
(days 1 and 15 of 4-week cycle) 
n = 28 
Schedule B 
(day 1 of 4-week cycle) 
n = 36 
Total  
N = 64 
 
CTCAE 
grade 3 
CTCAE 
grade 4 
CTCAE 
grade 5 
CTCAE  
grade 3–5 
CTCAE 
grade 3 
CTCAE 
grade 4 
CTCAE 
grade 5 
CTCAE  
grade 3–5 
CTCAE 
grade 3–5 
Blood and lymphatic system disorders 
Anaemia 
Febrile neutropenia 
Leukocytosis 
Leukopenia 
Neutropenia  
Thrombocytopenia 
5 (17·9) 
11 (39·3) 
9 (32·1) 
2 (7·1) 
1 (3·6) 
0 
0 
16 (57·1) 
1 (3·6) 
1 (3·6) 
1 (3·6) 
9 (32·1) 
2 (7·1) 
9 (32·1) 
0 
0 
0 
0 
0 
0 
0 
21 (75·0) 
12 (42·9) 
10 (35·7) 
3 (10·7) 
10 (35·7) 
2 (7·1) 
9 (32·1) 
6 (16·7) 
9 (25·0) 
14 (38·9) 
0 
2 (5·6) 
0 
2 (5·6) 
22 (61·1) 
2 (5·6) 
0 
0 
12 (33·3) 
8 (22·2) 
16 (44·4) 
0 
0 
0 
0 
0 
0 
0 
28 (77·8) 
11 (30·6) 
14 (38·9) 
0 
14 (38·9) 
8 (22·2) 
18 (50·0) 
49 (76·6) 
23 (35·9) 
24 (37·5) 
3 (4·7) 
24 (37·5) 
10 (15·6) 
27 (42·2) 
Infections and infestations 
Infection 
Pneumonia 
Pneumonia fungal 
Sepsis 
9 (32·1) 
2 (7·1) 
7 (25·0) 
2 (7·1) 
1 (3·6) 
0 
0 
0 
0 
0 
5 (17·9) 
0 
2 (7·1) 
0 
1 (3·6) 
14 (50·0) 
2 (7·1) 
9 (32·1) 
2 (7·1) 
2 (7·1) 
11 (30·6) 
1 (2·8) 
5 (13·9) 
2 (5·6) 
0 
1 (2·8) 
0 
1 (2·8) 
0 
0 
9 (25·0) 
0 
3 (8·3) 
0 
4 (11·1) 
21 (58·3) 
1 (2·8) 
9 (25·0) 
2 (5·6) 
4 (11·1) 
35 (54·7) 
3 (4·7) 
18 (28·1) 
4 (6·3) 
6 (9·4) 
Neoplasms benign, malignant and 
unspecified 
Neoplasm malignant 
0 
 
0 
0 
 
0 
1 (3·6) 
 
1 (3·6) 
1 (3·6) 
 
1 (3·6) 
1 (2·8) 
 
0 
1 (2·8) 
 
1 (2·8) 
4 (11·1) 
 
4 (11·1) 
6 (16·7) 
 
5 (13·9) 
7 (10·9) 
 
6 (9·4) 
Metabolism and nutrition disorders 5 (17·9) 0 0 5 (17·9) 3 (8·3) 2 (5·6) 0 5 (13·9) 10 (15·6) 
 12 
 
Hyperglycaemia 
Hypokalaemia 
Tumour lysis syndrome 
2 (7·1) 
0 
3 (10·7) 
0 
0 
0 
0 
0 
0 
2 (7·1) 
0 
3 (10·7) 
0 
2 (5·6) 
1 (2·8) 
0 
1 (2·8) 
0 
0 
0 
0 
0 
3 (8·3) 
1 (2·8) 
2 (3·1) 
3 (4·7) 
4 (6·3) 
Nervous system disorders 
Dizziness 
Syncope 
3 (10·7) 
2 (7·1) 
0 
1 (3·6) 
0 
0 
0 
0 
0 
4 (14·3) 
2 (7·1) 
0 
3 (8·3) 
0 
2 (5·6) 
1 (2·8) 
0 
0 
0 
0 
0 
4 (11·1) 
0 
2 (5·6) 
8 (12·5) 
2 (3·1) 
2 (3·1) 
Cardiac disorders 
Acute myocardial infarction 
2 (7·1) 
0 
0 
0 
1 (3·6) 
0 
3 (10·7) 
0 
2 (5·6) 
2 (5·6) 
0 
0 
0 
0 
2 (5·6) 
2 (5·6) 
5 (7·8) 
2 (3·1) 
Respiratory, thoracic and mediastinal 
disorders 
Dyspnoea 
Respiratory failure 
6 (21·4) 
 
4 (14·3) 
1 (3·6) 
0 
 
0 
0 
0 
 
0 
0 
6 (21·4) 
 
4 (14·3) 
1 (3·6) 
2 (5·6) 
 
3 (8·3) 
0 
1 (2·8) 
 
0 
0 
2 (5·6) 
 
0 
2 (5·6) 
5 (13·9) 
 
3 (8·3) 
2 (5·6) 
11 (17·2) 
 
7 (10·9) 
3 (4·7) 
Renal and urinary disorders 
Acute renal failure 
5 (17·9) 
2 (7·1) 
0 
0 
0 
0 
5 (17·9) 
2 (7·1) 
3 (8·3) 
1 (2·8) 
0 
0 
0 
0 
3 (8·3) 
0 
8 (12·5) 
2 (3·1) 
General disorders and administration 
site conditions 
Fatigue 
General physical health 
deterioration 
Mucosal inflammation 
Multi-organ failure 
Pyrexia 
3 (10·7) 
 
0 
1 (3·6) 
 
0 
0 
2 (7·1) 
1 (3·6) 
 
0 
1 (3·6) 
 
0 
0 
0 
3 (10·7) 
 
0 
1 (3·6) 
 
0 
1 (3·6) 
0 
7 (25·0) 
 
0 
3 (10·7) 
 
0 
1 (3·6) 
2 (7·1) 
13 (36·1) 
 
2 (5·6) 
3 (8·3) 
 
2 (5·6) 
0 
4 (11·1) 
1 (2·8) 
 
0 
1 (2·8) 
 
0 
0 
0 
3 (8·3) 
 
0 
1 (2·8) 
 
0 
2 (5·6) 
0 
17 (47·2) 
 
2 (5·6) 
5 (13·9) 
 
2 (5·6) 
2 (5·6) 
4 (11·1) 
24 (37·5) 
 
2 (3·1) 
8 (12·5) 
 
2 (3·1) 
3 (4·7) 
6 (9·4) 
Investigations 
Blood bilirubin increased 
8 (28·6) 
0 
0 
0 
0 
0 
8 (28·6) 
0 
7 (19·4) 
0 
4 (11·1) 
2 (5·6) 
0 
0 
11 (30·6) 
2 (5·6) 
19 (29·7) 
2 (3·1) 
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Blood lactate dehydrogenase 
increased 
Blood potassium decreased 
C-reactive protein increased 
1 (3·6) 
 
2 (7·1) 
4 (14·3) 
0 
 
0 
0 
0 
 
0 
0 
1 (3·6) 
 
2 (7·1) 
4 (14·3) 
2 (5·6) 
 
2 (5·6) 
4 (11·1) 
1 (2·8) 
 
0 
1 (2·8) 
0 
 
0 
0 
3 (8·3) 
 
2 (5·6) 
5 (13·9) 
4 (6·3) 
 
4 (6·3) 
9 (14·1) 
AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events. 
Data are n (%). 
*The CTCAE grade is considered independently for system organ class and for preferred terms. 
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Supporting Information 
Data S1. Methods 
Patients 
Adult patients with a confirmed diagnosis of AML according to the World Health Organization 
definition (excluding acute promyelocytic leukaemia) with previously untreated (except 
hydroxyurea) or relapsed/refractory disease and considered unsuitable for intensive induction or 
salvage therapy, were eligible for this study.  
Inclusion criteria also included life expectancy of ≥3 months and an Eastern Cooperative 
Oncology Group performance score ≤2, and patients were required to be eligible for low-dose 
cytarabine treatment and to be considered ineligible for intensive treatment. Patients were 
excluded if they had aspartate aminotransferase/alanine transaminase >2·5 × upper limit of 
normal [ULN], international normalized ratio >1.5 × ULN for patients not on therapeutic vitamin 
K antagonists, bilirubin >1·5 mg/dl, or serum creatinine >2·0 mg/dl. Patients with another 
malignancy that required treatment, known acute myeloid leukaemia central nervous system 
involvement, or left ventricular ejection fraction <50% in echocardiography or clinical congestive 
heart failure New York Heart Association grade III–IV, were also excluded. 
A patient’s ineligibility for intensive treatment was assessed by the investigator in 
agreement with the patient, based on a comprehensive documentation of the reasons for this 
assessment. This documentation included patient age, medical history, performance score, 
organ dysfunctions, co-morbidities, the patient’s informed decision and other relevant factors, 
supplemented with the investigator’s assessment of the reasons for evaluating the patient 
ineligible for intensive treatment. 
Study design 
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The primary endpoint was to determine the MTD of two BI 811283 schedules in combination 
with LDAC based on the incidence of DLTs. Further endpoints included incidence and intensity 
of AEs, PK of cytarabine with BI 811283, and response. Genetic risk group was assessed 
according to published criteria (Döhner et al, 2010). 
Patients were randomized to one of two schedules combining BI 811283 (24-hour 
intravenous infusion) with LDAC (20 mg twice daily subcutaneously, days 1–10 of a 4-week 
cycle). In Schedule A, patients received BI 811283 on days 1 and 15 of a 4-week cycle. In 
Schedule B, patients received BI 811283 on day 1 of a 4-week cycle. Dose escalation was 
conducted for each schedule following a 3+3 design. The starting BI 811283 dose was 5 mg. 
After the 5 mg dose cohorts, the protocol was amended to escalate the BI 811283 doses to 
approximately half the highest dose that was considered safe in a concurrent BI 811283 
monotherapy trial conducted in solid tumours (Mross et al, 2016). Accordingly, the second dose 
cohorts investigated BI 811283 at a dose of 15 mg per administration in Schedule A, and 40 mg 
in Schedule B. BI 811283 dosing frequency was chosen based on the expected duration of 
myelosuppression (Mross et al, 2016). The MTD was defined based on the occurrence of DLTs 
in the first cycle. DLT was defined as drug-related grade ≥3 non-haematologic toxicity 
(excluding: untreated nausea, untreated vomiting, grade 3 untreated diarrhoea, grade 3 febrile 
neutropenia and grade 3 infection with grade 3/4 neutropenia). In patients with incomplete 
haematologic recovery (CRi) or partial remission, persistent Grade 4 neutropenia or 
thrombocytopenia until 3 weeks after the end of the treatment cycle was also regarded as a 
DLT, unless the respective Grade 4 cytopenia was pre-existent. In patients who required 
platelet substitution to maintain a CTCAE Grade < 4 before treatment, a CTCAE Grade 4 
thrombocytopenia after treatment did not constitute a DLT. 
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The study protocol was approved by institutional review boards/ethics committees at 
participating centres. The study was conducted according to the Declaration of Helsinki 
guidelines, the International Conference on Harmonization-Good Clinical Practice Guidelines 
and local legislation. Written informed consent was obtained from all patients 
(NCT00632749/EudraCT 2007-005684-00/Study 1247.3). 
Criteria for therapy continuation  
At the end of each treatment cycle, the response to treatment was assessed. To continue 
treatment with further cycles, the following criteria had to be met: absence of disease 
progression, neutrophils ≥500/μL (0·5 × 109/L) and platelets ≥25,000/μL (25 × 109/L), unless 
Common Terminology Criteria for Adverse Events (CTCAE) grade 4 neutropenia or 
thrombocytopenia was pre-existing; and acceptable tolerability (in case of a dose-limiting toxicity 
[DLT], patients could continue therapy only after recovery from DLT to CTCAE levels that would 
allow further therapy and only with a reduced dose). 
Safety assessments 
AEs were graded according to Common Terminology Criteria for Adverse Events version 3.0 
recording date of onset, end date, treatment/action required and outcome. Safety laboratory 
examinations included haematology, biochemistry and coagulation parameters. A 12-lead 
resting electrocardiogram was performed at screening and at end-of-treatment visits. 
Efficacy assessments 
Response was assessed in the peripheral blood and bone marrow at the end of each treatment 
cycle. In case of extramedullary manifestations of leukaemia, response assessment by imaging 
was used to complement the blood and bone marrow assessment. Responses were assessed 
according to published criteria (Döhner et al, 2010). 
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Pharmacokinetics 
Blood was collected at specified time points during the first treatment cycle to determine plasma 
concentrations of BI 811283 and cytarabine. BI 811283 base salt concentrations were 
determined by a validated high-performance liquid chromatography tandem mass spectrometry 
assay (Nuvisan GmbH, Neu-Ulm, Germany). Analysis of the plasma samples for cytarabine was 
conducted at SGS Cephac Europe, Saint-Benoît Cedex, France. 
Statistical analysis 
All analyses were descriptive and exploratory by nature.  
 
  
 18 
 
Table SI. Patient demographic and baseline disease characteristics. 
 Schedule A 
(days 1 and 15 of  
4-week cycle) 
n = 28 
Schedule B 
(day 1 of  
4-week cycle) 
n = 36 
Total  
N = 64 
Male/female, n (%) 12 (42·9)/16 (57·1) 22 (61·1)/14 (38·9) 34 (53·1)/30 (46·9) 
Age, years (median, range) 73 (49‒89) 73 (52–83) 73 (49–89) 
ECOG performance score, n (%) 
0 
1 
2 
 
6 (21·4) 
15 (53·6) 
7 (25·0) 
 
5 (13·9) 
22 (61·1) 
9 (25·0) 
 
11 (17·2) 
37 (57·8) 
16 (25·0) 
Previously untreated, n (%) 
Relapsed/refractory to prior therapy, n (%) 
Number of previous anti-cancer 
therapies (median, range)* 
20 (71·4) 
8 (28·6) 
 
2·5 (1–7) 
24 (66·7) 
12 (33·3) 
 
2·5 (1–7) 
44 (68·8) 
20 (31·3) 
 
2·5 (1–7) 
AML considered secondary, n (%) 
Due to: 
Preceding MDS 
Preceding MPN 
Prior alkylating agent therapy 
Other reason 
10 (35·7) 
 
8 (80·0) 
1 (10·0)  
1 (10·0)  
0 
15 (41·7) 
 
10 (66·7) 
2 (13·3)  
1 (6·7)  
2 (13·3)  
25 (39·1) 
 
18 (72·0) 
3 (12·0) 
2 (8·0) 
2 (8·0) 
Genetic risk classification, n (%)† 
Adverse  
Favourable 
Intermediate I 
Intermediate II 
Missing 
 
10 (35·7) 
1 (3·6) 
10 (35·7) 
1 (3·6) 
6 (21·4) 
 
12 (33·3) 
1 (2·8) 
10 (27·8) 
5 (13·9) 
8 (22·2) 
 
22 (34·4) 
2 (3·1) 
20 (31·3) 
6 (9·4) 
14 (21·9) 
AML, acute myeloid leukaemia; ECOG, Eastern Cooperative Oncology Group; MDS, 
myelodysplastic syndrome; MPN, myeloproliferative neoplasms. 
*Includes previous therapy for both AML and any other malignancy.  
†According to European Leukemia Net criteria (Döhner et al, 2010).  
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Table SII. Incidence of AEs by dose.  
 Schedule A (days 1 and 15 of 4-week cycle) 
BI 811283 dose 
5 mg  
(n = 4) 
15 mg  
(n = 3) 
30 mg  
(n = 3) 
60 mg  
(n = 4) 
100 mg 
(n = 7) 
120 mg 
(n = 7) 
AE, n (%)       
Leukopenia 0 0 1 (33·3) 1 (25·0) 4 (57·1) 5 (71·4) 
Anaemia 1 (25·0) 2 (66·7) 1 (33·3) 1 (25·0) 5 (71·4) 5 (71·4) 
Dyspnoea 0 1 (33·3) 1 (33·3) 1 (25·0) 2 (28·6) 4 (57·1) 
 Schedule B (day 1 of 4-week cycle) 
BI 811283 dose 
5 mg 
(n = 4) 
40 mg 
(n = 4) 
80 mg 
(n = 5) 
160 mg 
(n = 3) 
240 mg 
(n = 7) 
300 mg 
(n = 4) 
360 mg  
(n = 3) 
420 mg 
(n = 6) 
AE, n (%)         
Leukopenia 1 (25·0) 1 (25·0) 1 (20·0) 1 (33·3) 3 (42·9) 2 (50·0) 3 (100·0) 2 (33·3) 
AE, adverse event. 
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Table SIII. Best overall response. 
Schedule A (days 1 and 15 of 4-week cycle) 
BI 811283 dose 
5 mg  
(n = 4) 
15 mg  
(n = 3) 
30 mg  
(n = 3) 
60 mg  
(n = 4) 
100 mg  
(n = 7) 
120 mg  
(n = 7) 
Total  
(N = 28), 
n (%) 
  
Best overall response, n 
CR 
CRi 
PR 
No change 
PD 
Missing 
0 
0 
0 
1 
2 
1 
0 
0 
0 
2 
1 
0 
0 
0 
0 
1 
2 
0 
1 
0 
0 
1 
1 
1 
0 
0 
0 
2 
4 
1 
1 
0 
0 
3 
1 
2* 
2 (7·1) 
0 
0 
10 (35·7) 
11 (39·3) 
5 (17·9) 
  
Schedule B (day 1 of 4-week cycle) 
BI 811283 dose 
5 mg 
(n = 4) 
40 mg 
(n = 4) 
80 mg 
(n = 5) 
160 mg 
(n = 3) 
240 mg 
(n = 7) 
300 mg 
(n = 4) 
360 mg 
(n = 3) 
420 mg 
(n = 6) 
Total 
(N = 36), 
n (%) 
Best overall response, n  
CR 
CRi 
PR 
No change 
PD 
Missing 
1 
0 
0 
1 
2 
0 
0 
0 
1 
2 
0 
1 
1 
0 
0 
3 
0 
1* 
1 
0 
0 
2 
0 
0 
1 
0 
0 
4 
2 
0 
0 
0 
0 
2 
2 
0 
1 
1 
0 
1 
0 
0 
0 
0 
0 
2 
2 
2 
5 (13·9) 
1 (2·8) 
1 (2·8) 
17 (47·2) 
8 (22·2) 
4 (11·1) 
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CR, complete remission; CRi, complete remission with incomplete hematologic recovery; PR, partial remission; PD, progressive 
disease. 
*One patient not evaluable for response.
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Fig S1. Geometric mean plasma concentration–time profiles of BI 811283 during and after 
the 24-hour infusion of BI 811283. (A) Day 1, cycle 1, Schedule A. (B) Day 15, cycle 1, 
Schedule A. (C) Day 1, cycle 1, Schedule B.  
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Fig S2. Geometric mean plasma concentration–time profiles of cytarabine. (A) Schedule A. 
(B) Schedule B. 
 
 
 
 
 
 
